These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3471283)

  • 61. An acute leukaemia augured before clinical signs by blood group antigen abnormalities and low levels of A and H blood group transferase activities in erythrocytes.
    Lopez M; Bonnet-Gajdos M; Reviron M; Janvier D; Huet M; Salmon C
    Br J Haematol; 1986 Jul; 63(3):535-9. PubMed ID: 3089272
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase.
    Sonneck K; Mannhalter C; Krauth MT; Sperr WR; Schwarzinger I; Fonatsch C; Haas O; Geissler K; Valent P
    Eur J Haematol; 2005 Jul; 75(1):73-7. PubMed ID: 15946315
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined differentiation therapy in myelodysplastic syndrome with retinoid acid, 1 alpha,25 dihydroxyvitamin D3, and prednisone.
    Blazsek I; Musset M; Boulé D; Labat ML; Bringuier MF; Comisso M; Le Maignan C; Ribaud P; Mathé G; Misset JL
    Cancer Detect Prev; 1992; 16(4):259-64. PubMed ID: 1458517
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
    Bacher U; Kern W; Alpermann T; Schnittger S; Kohlmann A; Klein HU; Dugas M; Haferlach C; Haferlach T
    Leukemia; 2011 Aug; 25(8):1361-4. PubMed ID: 21494258
    [No Abstract]   [Full Text] [Related]  

  • 65. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow.
    Tamura S; Kanamaru A; Takemoto Y; Kakishita E; Nagai K
    Br J Haematol; 1993 Jun; 84(2):219-26. PubMed ID: 8398821
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
    Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Diagnosis and treatment strategy for de novo AML with trilineage myelodysplasia].
    Kuriyama K
    Rinsho Ketsueki; 1994 Mar; 35(3):267-71. PubMed ID: 8158847
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Acute biphenotypic leukaemia (myeloid and null-ALL type) supervening in a myelodysplastic syndrome.
    Eridani S; Chan LC; Halil O; Pearson TC
    Br J Haematol; 1985 Nov; 61(3):525-9. PubMed ID: 3864486
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acute myeloblastic leukemia.
    Molina CA; Rodríguez MJ; de Marcos NS; Font P
    Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.
    Chen X; Newell LF; Xie H; Walter RB; Pagel JM; Sandhu VK; Becker PS; Hendrie PC; Abkowitz JL; Appelbaum FR; Estey EH
    Leukemia; 2015 Aug; 29(8):1779-80. PubMed ID: 25650090
    [No Abstract]   [Full Text] [Related]  

  • 72. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
    Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases.
    Lu CM; Murata-Collins JL; Wang E; Siddiqi I; Lawrence H
    Am J Hematol; 2006 Dec; 81(12):963-8. PubMed ID: 16917916
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Complex karyotype is a marker of very poor prognosis in over 70-year-old patients with acute myeloid leukemia and extended types of myelodysplastic syndrome and high comorbidity index].
    Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Ivanova MP; Petrova EV; Zapreeva IM; Tiranova SA; Potikhonova NA
    Ter Arkh; 2012; 84(7):16-21. PubMed ID: 23038966
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
    Solly F; Koering C; Mohamed AM; Maucort-Boulch D; Robert G; Auberger P; Flandrin-Gresta P; Adès L; Fenaux P; Kosmider O; Tavernier-Tardy E; Cornillon J; Guyotat D; Campos L; Mortreux F; Wattel E
    Clin Cancer Res; 2017 Jun; 23(12):3025-3034. PubMed ID: 27881579
    [No Abstract]   [Full Text] [Related]  

  • 77. [Metastatic aspergillus panniculitis in blast transformation of a myelodysplastic syndrome and agranulocytosis].
    Skaria AM; Chavaz P; Hauser C
    Hautarzt; 1995 Aug; 46(8):579-81. PubMed ID: 7558830
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Wood SM; Meyers CA; Faderl S; Kantarjian HM; Pierce SA; Garcia-Manero G
    Am J Hematol; 2011 Nov; 86(11):950-2. PubMed ID: 21919036
    [No Abstract]   [Full Text] [Related]  

  • 79. Loss and Reappearance of A Antigen After Chemotherapy Leading to Blood Group Discrepancy in Acute Myeloid Leukemia: A Case Report.
    Prakash S; Mohapatra S; Bhagavathi MS; Das N; Krushna Ray G; Mukherjee S
    Lab Med; 2021 Sep; 52(5):509-513. PubMed ID: 33724429
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Blood group change in acute myeloid leukaemia.
    Hocking DR
    Med J Aust; 1971 Oct; 2(18):902-3. PubMed ID: 5288193
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.